

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI60354

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Hayfin Services LLP		12/18/2023	Limited Liability Partnership: UNITED KINGDOM
<b>RECEIVING PARTY DATA</b>			
<b>Company Name:</b>	ADMA Biologics, Inc.		
<b>Street Address:</b>	5800 Park of Commerce Blvd., NW		
<b>City:</b>	Boca Raton		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33487		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Company Name:</b>	ADMA Biomanufacturing, LLC		
<b>Street Address:</b>	5800 Park of Commerce Blvd., NW		
<b>City:</b>	Boca Raton		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33487		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5967728	ASCENIV	
<b>Registration Number:</b>	4318477	BIVIGAM	
<b>Registration Number:</b>	3015857	CIVACIR	
<b>Registration Number:</b>	2635779	NABI-HB	
<b>Registration Number:</b>	6652223	ADVANTAGE IG	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2027393001		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2027395866		
<b>Email:</b>	felicia.gordon@morganlewis.com		
<b>Correspondent Name:</b>	Felicia Gordon		
<b>Address Line 1:</b>	1111 Pennsylvania Avenue, NW		

CH \$140.00.00 87012361

**Address Line 4:** Washington, DISTRICT OF COLUMBIA 20004

**ATTORNEY DOCKET NUMBER:** 124650.0034

**NAME OF SUBMITTER:** FELICIA GORDON

**SIGNATURE:** FELICIA GORDON

**DATE SIGNED:** 02/29/2024

**Total Attachments: 12**

source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page1.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page2.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page3.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page4.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page5.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page6.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page7.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page8.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page9.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page10.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page11.tif  
source=Hayfin Services LLP - Release of IP Security Interest (Executed)#page12.tif

**RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY** (the “Release”) is made as of December 18, 2023, by **HAYFIN SERVICES LLP**, as administrative agent for all Lenders that are party to the Credit Agreement as defined herein (the “Agent”), in favor of **ADMA BIOLOGICS, INC., ADMA BIOMANUFACTURING, LLC**, and all other Grantors under the Security Agreement (the “Grantors”). Capitalized terms used but not otherwise defined herein shall have the meaning given to them in the Security Agreement or below-defined Credit Agreement.

WHEREAS, the Grantors entered into that certain Credit Agreement, dated as of March 23, 2022, among certain of the Grantors, the Agent, the Lenders and the other parties thereto, as such was amended, by that certain Amendment No. 1 to Credit Agreement and Guaranty, dated as of March 22, 2023, that certain Amendment No. 2 to Credit Agreement and Guaranty, dated as of May 1, 2023, and as may be further amended prior to the date hereof (the “Credit Agreement”), whereby the Lenders agreed to make certain loans and to extend certain letters of credit to the Borrower (collectively, the “Loans”);

WHEREAS, pursuant to the Credit Agreement, and as a condition of the Lenders making the Loans, the Grantors entered into that certain Security Agreement, dated as of March 23, 2022, among the Grantors and the Agent for the benefit of the Lenders, and all annexes, exhibits or schedules thereto, as each may have been amended, restated, supplemented or otherwise modified from time to time (the “Security Agreement”), whereby the Grantors were obligated to enter into certain security agreements, instruments and documents in favor of Agent;

WHEREAS, in furtherance of the Credit Agreements and pursuant to the Security Agreement, the Grantors executed and delivered the following security agreements, instruments and documents in favor of Agent, including, without limitation, the following:

- (i) Patent Security Agreement, dated as of March 23, 2022, by ADMA Biologics, Inc. in favor of Agent, as recorded with the U.S. Patent and Trademark Office (the “USPTO”) on March 23, 2022 at Reel 059376/Frame 0718; and
- (ii) Trademark Security Agreement, dated as of March 23, 2022, by ADMA Biologics, Inc. and ADMA Biomufacturing, LLC in favor of Agent, as recorded with the USPTO on March 23, 2022 at Reel 007669/Frame 0215 (collectively, the “Intellectual Property Security Agreements”);

WHEREAS, pursuant to the Intellectual Property Security Agreements, the Grantors granted the Agent, on behalf of itself and the Secured Parties, a continuing security interest in all of each applicable Grantor’s right, title and interest in, to and under certain Intellectual Property collateral, including, without limitation, the registered Patents and Patent applications, and Trademark registrations and applications for Trademark registration identified on Exhibit 1 attached hereto (collectively, the “Intellectual Property Collateral”);

WHEREAS, the Grantors have satisfied in full the terms of the Credit Agreement and Security Agreement and have requested that the Agent, on behalf of itself and the Lenders, (a) terminate and release the security interest in the Intellectual Property Collateral, and (b) provide a document suitable for recording with the USPTO for the release, relinquishment and discharge of its security interest in the Intellectual Property Collateral; and

DB1/ 142974005.2

300363950

1606133219.3

WHEREAS, the Loans and all other obligations under the Credit Agreement and Security Agreement have been paid in full or fulfilled, and there are no outstanding obligations remaining due and owing under the Credit Agreement and Security Agreement, which have been terminated, the Agent, on behalf of itself and the Lenders, desires to terminate and grant a release of its security interest in the Intellectual Property Collateral and to terminate and release the Intellectual Property Security Agreements as provided in this Release.

NOW THEREFORE, for good and valuable consideration previously tendered by the Grantors, the receipt and sufficiency of which are hereby acknowledged, the Agent, on behalf of itself and the Lenders, does hereby agree as follows:

1. The Agent, on behalf of itself and the Lenders, hereby: (a) terminates the Intellectual Property Security Agreements; (b) releases, relinquishes, terminates and discharges, without recourse, its security interest in the Intellectual Property Collateral in its entirety; and (c) retransfers and reassigns to the applicable Grantors any and all right, title and interest of any nature whatsoever which it may hold in, to or under any of the Intellectual Property Collateral, including, without limitation, the registered Patents and Patent applications, and Trademark registrations and applications for Trademark registration identified on Exhibit 1 attached hereto, and all associated common law rights and goodwill appurtenant thereto.

2. The Agent, on behalf of itself and the Lenders, authorizes the Grantors to record this Release with the USPTO and any other applicable governmental authority.

3. At the request and sole expense of the Grantors, the Agent, on behalf of itself and the Lenders, agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions necessary to carry out the purposes of this Release.


4. All capitalized terms used but not defined in the Release shall have the meaning set forth in the Credit Agreement and Intellectual Property Security Agreements, as applicable. The Release shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any conflicts of law principles.

*[Signature page follows]*

IN WITNESS WHEREOF, the undersigned has caused this Release to be duly executed as of the date first written above.

**HAYFIN SERVICES LLP,**

as Agent

By:  \_\_\_\_\_

Name: Erica Hughes

Title: Authorised Signatory

[Signature Page to Release of Security Interest in Intellectual Property]

# EXHIBIT 1

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0755**

# PATENTS

TITLE OF INVENTION	SERIAL/ PATENT NO.	FILING/ REGISTRATION DATE	OWNER	COUNTRY	FAMILY
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Patent: 9,107,906 B1	08/18/2015	ADMA Biologics, Inc.	USA	33978
	Patent: 9,714,283 B2	07/25/2017	ADMA Biologics, Inc.	USA	
	Patent: 9,815,886 B2	11/14/2017	ADMA Biologics, Inc.	USA	
	Patent: 9,969,793 B2	05/15/2018	ADMA Biologics, Inc.	USA	
	Patent: 10,683,343 B2	06/16/2020	ADMA Biologics, Inc.	USA	
	App. No. 16/901,993	06/15/2020	ADMA Biologics, Inc.	USA	
	App. No. PCT/US2015/057715	10/28/2015	ADMA Biologics, Inc.	PCT	
	Patent: 242156	10/19/2015	ADMA Biologics, Inc.	Israel	
	Patent: 263819	06/02/2021	ADMA Biologics, Inc.	Israel	
	Patent: 2724058	10/20/2015	ADMA Biologics, Inc.	Russia	
	Patent: 370191	10/21/2015	ADMA Biologics, Inc.	Mexico	
	App. No. 15190963.7	10/22/2015	ADMA Biologics, Inc.	European Patent	
	App. No. 16113712.2	10/22/2015	ADMA Biologics, Inc.	Hong Kong	
	App. No. 2015246157	10/23/2015	ADMA Biologics, Inc.	Australia	
App. No. 2021202598	04/27/2021	ADMA Biologics, Inc.	Australia (DIV)		

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0756**

	App. No. 2910491	10/23/2015	ADMA Biologics, Inc.	Canada	
	Patent: 2015/07987	10/27/2015	ADMA Biologics, Inc.	South Africa	
	Patent: 2017/07303	10/26/2017	ADMA Biologics, Inc.	South Africa	
	App. No. BR1020150273878	10/28/2015	ADMA Biologics, Inc.	Brazil	
	App. No. BR122021025745 0	12/20/2021	ADMA Biologics, Inc.	Brazil	
ANTI- PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION	Patent: 10,259,865	03/15/2017	ADMA Biologics, Inc.	USA	35158
	Patent: 11,084,870	08/10/2021	ADMA Biologics, Inc.	USA	
	App. No. 2018201803	03/14/2018	ADMA Biologics, Inc.	Australia	
	App. No. 102018005192-0	03/15/2018	ADMA Biologics, Inc.	Brazil	
	App. No. 2998067	03/13/2018	ADMA Biologics, Inc.	Canada	
	Patent: 3375789*	03/15/2018	ADMA Biologics, Inc.	Europe	
	App. No. 258116	03/14/2018	ADMA Biologics, Inc.	Israel	
	App. No. MX/a/2018/003159	03/14/2018	ADMA Biologics, Inc.	Mexico	
	App. No. 2018-109264	03/15/2018	ADMA Biologics, Inc.	Russia	
	App. No. PCT/US2018/022701	03/15/2018	ADMA Biologics, Inc.	PCT	
	App. No. 2020-500018	03/15/2018	ADMA Biologics, Inc.	Japan	
	App. No. 10-2019- 7030200	03/15/2018	ADMA Biologics, Inc.	Korea	
	App. No. 11201908573Q	03/15/2018	ADMA Biologics, Inc.	Singapore	
	App. No. 201917041759	03/15/2018	ADMA Biologics, Inc.	India	

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0757**



	App. No. 17/397.915	08/09/2021	ADMA Biologics, Inc.	USA	
	App. No. 21212658.5	12/07/2021	ADMA Biologics, Inc.	Europe	
	*Validated in AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, NL, PT, SE				
IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS	App. No. 17/196.846 (ABN)	03/09/2021	ADMA Biologics, Inc.	USA	38320
	App. No. PCT/US2021/021564	03/09/2021	ADMA Biologics, Inc.	USA	
COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS	App. No. 17/391.990 (ABN)	08/02/2021	[TBD]	USA	38687
	App. No. PCT/US2021/044205 (ABN)	08/02/2021	[TBD]	USA	
AUTOMATED DOCUMENT MANAGEMENT SYSTEM	App. No. 16/526.106 (ABN)	07/30/2019	ADMA Biologics, Inc.	USA	37815
	App. No. PCT/US2019/044085 (ABN)	07/30/2019	ADMA Biologics, Inc.	USA	
CONJUGATED ANTIBODIES FOR TREATING DISEASE	App. No. 63/245.180	09/16/2021	ADMA Biologics, Inc.	USA	39814

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0758**

# TRADEMARKS

## Active Trademarks:

Trademark	Country	Appl. Status	Appl./Reg. No.	Appl./Reg Date	Renewal Date	Owner	Goods
ASCENIV	IR-Australia	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Great Britain/UK	Registered	UK00801352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Egypt	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-European Union	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	International	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Israel	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	IR-Tunisia	Registered	IR 1352668	10-May-2017	10-May-2027	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ASCENIV	U.S.A.	Registered	5,967,728	21-Jan-2020	21-Jan-2026	ADMA Biologics, Inc.	Cl. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
BIVIGAM	U.S.A.	Registered	4,318,477	9-Apr-2013	9-Apr-2023	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin for treatment of primary immunodeficiency disease
CTVACIR	IR-European Union	Registered	IR 887996	9-May-2006	9-May-2026	ADMA Biomufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
CTVACIR	IR-Great Britain/UK	Registered	UK00800887996	9-May-2006	9-May-2026	ADMA Biomufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
CTVACIR	International (WIPO)	Registered	IR 887996	9-May-2006	9-May-2026	ADMA Biomufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0759**

CIYACIR	U.S.A.	Registered	3,015,857	15-Nov-2005	15-Nov-2025	ADMA Biomufacturing, LLC	Cl. 5: Anti-infective pharmaceutical preparations
NABI-HIB	Brazil	Registered	829811818	17-Jan-2012	17-Jan-2032	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	European Union	Registered	3109048	31-Jan-2005	25-Mar-2023	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	Great Britain/UK	Registered	UK00903109	31-Jan-2005	25-Mar-2023	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	Hong Kong	Registered	301116549	15-May-2008	14-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	International	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	IR-Ireland	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	Israel	Registered	211681	13-Apr-2010	18-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	Taiwan	Registered	1,49353	16-Feb-2009	15-Feb-2029	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	IR-Turkey	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	U.S.A.	Registered	2,635,779	15-Oct-2002	15-Oct-2022	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
NABI-HIB	IR-Vietnam	Registered	IR 964372	13-May-2008	13-May-2028	ADMA Biomufacturing, LLC	Cl. 5: Immune globulin preparations for prevention and treatment of hepatitis
ADVANTAGE IG	U.S.A.	Registered	6,652,223	22-Feb-2022	22-Feb-2032	ADMA BIOLOGICS, INC.	Cl. 36: Financial administration of medication reimbursement programs and services; providing financial consultancy services and assistance for health care; providing information on health insurance benefits and patient assistance

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0760**

**Inactive Trademarks:**

<b>Trademark</b>	<b>Country</b>	<b>Status</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Owner</b>	<b>Goods</b>
ADVIGA	IR-Australia	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Egypt	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-European Union	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	International (WIPO)	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Israel	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	IR-Tunisia	Not Active	IR 1352669	10-May-2017	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
ADVIGA	U.S.A.	Not Active	87012,343	25-APR-2016	ADMA Biologics	C1. 5: Pharmaceutical preparations, namely, IVIG (Intravenous immunoglobulin)
BIVIGAM CARES	U.S.A.	Not Active	4,430,011	05-Nov-2013	ADMA Biologics	C1. 36: Insurance services, namely, insurance administration services to assist patients
FOR UNCOMPROMISED LIVING	U.S.A.	Not Active	4,495,929	11-Mar-2014	ADMA BioManufacturing, LLC	C1. 16: Brochures about primary Immunodeficiency medicine
GAMIVRA	IR-Australia	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Egypt	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - European Union	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	International (WIPO)	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Israel	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	IR - Tunisia	Not Active	IR 1267446	31-Aug-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
GAMIVRA	U.S.A.	Not Active	86/520,117	23-Jun-2015	ADMA Biologics	C1. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
INSPIRED	U.S.A.	Not Active	4,404,516	17-Sep-2013	ADMA Biologics	C1. 16: Publications, namely, patient support booklets, pamphlets, patient guides, support

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0761**

SUPPORT FOR THE PL COMMUNITY						newsletters, brochures, and bulletins in the fields of primary immunodeficiency (PI) medicine and support for patients with that diagnosis  Cl. 44: Providing a web site featuring medical information; providing an internet website for medical professionals and medical patients
NABI-HIB	Canada	Not Active	1043185	17-Feb-2004	Nabi Pharmaceuticals	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HIB	Egypt	Not Active	220944	29-Nov-2010	Nabi Pharmaceuticals	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HIB	India	Not Active	1688433	13-May-2008	ADMA Biomanufacturing, LLC	Cl. 5: Immune globulin preparation for the prevention or treatment of hepatitis
RESPIMMUNE	U.S.A.	Not Active	86414,489	03-Oct-2014	ADMA Biologies	Cl. 5: Pharmaceutical preparations, namely, immune globulins
RESYNRUS	IR - Australia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Egypt	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Europe	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	International (WIPO)	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Israel	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Tunisia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	U.S.A.	Not Active	86520,133	23-Jun-2015	ADMA Biologies	Cl. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders

DB1/ 142974005.2

300363950  
1606133219.3

**TRADEMARK**  
**REEL: 008357 FRAME: 0762**

SUPPORT FOR THE PL COMMUNITY						newsletters, brochures, and bulletins in the fields of primary immunodeficiency (PI) medicine and support for patients with that diagnosis  CI. 44: Providing a web site featuring medical information; providing an internet website for medical professionals and medical patients
NABI-HIB	Canada	Not Active	1043185	17-Feb-2004	Nabi Pharmaceuticals	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HIB	Egypt	Not Active	220944	29-Nov-2010	Nabi Pharmaceuticals	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
NABI-HIB	India	Not Active	1688433	13-May-2008	ADMA Biomanufacturing, LLC	CI. 5: Immune globulin preparation for the prevention or treatment of hepatitis
RESPIMMUNE	U.S.A.	Not Active	86414,489	03-Oct-2014	ADMA Biologics	CI. 5: Pharmaceutical preparations, namely, immune globulins
RESYNRUS	IR - Australia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Egypt	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Europe	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	International (WIPO)	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Israel	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	IR - Tunisia	Not Active	IR 1267445	31-Aug-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders
RESYNRUS	U.S.A.	Not Active	86520,133	23-Jun-2015	ADMA Biologics	CI. 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders

DB1/ 142974005.2

300363950  
1606133219.3